Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Accumulated Expenses data on file, last reported at $17.0 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $17.0 million, up 407.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.0 million (up 407.77% YoY), and the FY2025 annual result was $19.0 million, down 5.0% from the prior year.
• Other Accumulated Expenses declined to $17.0 million in Q1 2026 per RARE's latest filing, from $19.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $59.9 million in Q3 2022 and troughed at $3.3 million in Q1 2025.
• A 5-year average of $34.0 million and a median of $36.8 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses slumped 93.33% in 2025, then soared 407.77% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $52.2 million in 2022, then dropped by 2.64% to $50.8 million in 2023, then plunged by 60.63% to $20.0 million in 2024, then declined by 5.0% to $19.0 million in 2025, then decreased by 10.53% to $17.0 million in 2026.
• Business Quant data shows RARE's Other Accumulated Expenses at $17.0 million in Q1 2026, $19.0 million in Q4 2025, and $19.0 million in Q3 2025.